Novartis' Radioligand Therapy Hits Primary Endpoint Goal In Prostate Cancer Study

Novartis AG NVS says that its Phase 3 VISION study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients. Details were not disclosed.

  • Investigators tried to treat progressive PSMA-positive metastatic castration-resistant prostate cancer patients, comparing it against the standard of care.
  • The VISION trial results will be presented at an upcoming medical meeting and included in U.S. and E.U. regulatory submissions.
  • 177Lu-PSMA-617 is an investigational PSMA-targeted radioligand therapy, a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope.
  • After administration into the bloodstream, 177Lu-PSMA-617 binds to prostate cancer cells that express PSMA, a transmembrane protein, with high tumor-to-normal tissue uptake.
  • Once bound, emissions from the radioisotope damage tumor cells, disrupting their ability to replicate and triggering cell death.
  • Price Action: NVS shares are trading 0.49% lower at $86.09 in market trading hours on the last check Tuesday.

Posted In: prostate cancerBiotechNewsHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.